L-ascorbic acid/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Increases acute kidney injury incidence (any grade)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“A higher incidence of acute kidney injury (AKI) was found in the vitamin C-treated group (68.4%) than in the control group (35.0%), which was statistically significant (p=0.04), according to the Kidney Disease: Improving Global Outcomes (KDIGO) definition.”
Quoted verbatim from A randomized trial of ascorbic acid for the prevention of post-reperfusion syndrome during liver transplantation.. - Study
- RCT
- Dose
- 1500 mg intravenous bolus in 100 mL saline during the anhepatic phase, once
- Population
- Adults undergoing liver transplantation, single-centre pilot trial of 39 patients; a single 1500 mg intravenous ascorbic acid bolus before graft reperfusion versus 0.9% saline
A randomized trial of ascorbic acid for the prevention of post-reperfusion syndrome during liver transplantation.2025PMID:40719561Permalink
Keep reading
- Everything the graph holds on L-ascorbic acid
- Every compound studied against Acute kidney injury incidence (any grade)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PATMHD26Z5Y653HRD1CHHJ